Stone Incrustation: A Relevant Complication of the Intraprostatic Spiral

Clinical relevance of urethral stents (urospiral 2™) placement in patients with prostatic obstacle and concomitant high‐risk surgical status or neurological diseases: A feasibility and safety study

“…As has been previously reported with spiral metal and polyurethane stents, we did not encounter difficulties removing stents except in one patient, whose stent was heavily encrusted 10, 13. This complication has been reported to be as high as 66% in long‐term indwelling metal stents 18. As recommended by the manufacturer (Coloplast, Inc.), Urospiral 2™ should be removed within 6 months of insertion to prevent encrustation.…”

“…De novo LUTS have been commonly reported in all series, but are not easy to determine in retrospective studies such as this one due to the lack of validated questionnaire 9, 10, 13–15, 17, 18. We found a 32% incidence of moderate filling symptoms, which resolved spontaneously or with the use of anticholinergic medications.…”

“…Few series have demonstrated the efficacy of TUSs in relieving prostatic obstruction in populations including only patients deemed unfit for conventional ablative surgery (Table III). 9, 10, 13–15, 17, 18 To our knowledge, no previous studies have evaluated the efficacy of Urospiral 2™ in patients with BPH and concomitant high‐risk surgical status or neurological diseases. Well‐known advantages of TUSs include ease of placement and removal under topical anesthesia.…”